BLUEBIRD BIO INC. -  

Ranking results:

Past rankings:

2019
Criterium:Position:
Overall Score:> 1000
Total Number of Projects:> 1000

Ranking timeline:

Project Participation Performance(2019-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 1
As coordinator: 0
As participant: 1
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2019 0 10.999.316 0 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
BIOSCI CONSULTING BVBA1
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG1
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL1
COVANCE LABORATORIES1
DYNAMIC421
F HOFFMANNLA ROCHE1
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V1
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE1
INSTITUT DE RECHERCHES SERVIER1
JDRF INTERNATIONAL1
LEIDS UNIVERSITAIR MEDISCH CENTRUM1
LUND UNIVERSITY1
MEDIZINISCHE HOCHSCHULE HANNOVER1
MEDIZINISCHE UNIVERSITAT INNSBRUCK1
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN1
MERCK SHARP & DOHME CORP1
NOVARTIS PHARMA1
SANOFIAVENTIS1
TCURX1
THE UNIVERSITY OF TUEBINGEN1
TRANSGENE1
UNIVERSITAET LEIPZIG1
UNIVERSITAETSKLINIKUM JENA1
UNIVERSITAETSKLINIKUM WUERZBURG KLINIKUM DER BAYERISCHEN JULIUSMAXIMILIANSUNIVERSITAT1
UNIVERSITE DU LUXEMBOURG1
UNIVERSITEIT TWENTE1
UNIVERSITY OF OSLO1

Constancy:

Total number of partners: 27
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 27
Frequent / Rare Partner Ratio: 0

Project overview:

Start dateProjectacronymrolefundingpartners
2019-12-01Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies imSAVARparticipant10.999.31628